 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jul 01, 2020 |
| Title |
Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Hepatic fibrosis is defined as a pathological process, and activation of hepatic stellate cells (HSCs) is believed to be the key event of liver fibrosis. Additionally, activated HSCs may participate in the formation of the tumor microenvironment. Polaprezinc, a protector of the gastric mucosa, has been recently demonstrated to be an inhibitor of liver fibrosis in a mouse model.Proliferation and colony formation assays were performed to determinethe inhibitory effects of polaprezinc on the growth of LX-2 and hepG2 cells. A migration assay was used to evaluate the change in mobility of LX-2 cells and quantitative polymerase chain reactionwas performed to detect the expression levels of key markers of fibrosis. Finally, a gene chip assay for polaprezinc-treated hepG2 cells was performed to evaluate the effectof polaprezinc on the hepG2 gene expression profile.The proliferation assay indicated that polaprezinc may inhibit the LX-2 cell proliferation and the migration assays confirmed the inhibition of mobility. The expression levels of fibrotic markers such as collagen I, fibronectin and α-smooth muscle actinweredownregulated followingpolaprezinc treatment. The proliferation activity of polaprezinc-treated hepG2 cells was reduced and the gene chip assay indicated that series of gene expression changes associated with cancer migration, cell skeletal organization and proliferation had occurred.In conclusion, polaprezinc treatment mayinhibit the proliferation of hepatocellular carcinoma cells and reverse liver fibrosis by deactivating HSCs. The present findings suggest that polaprezinc provides a novel treatment for patients with gastritis complicated with cirrhosis
|
| |
|
| Overall design |
one sample was treatment with polaprezinc at 0 µg/ml ，and another was treatment with polaprezinc at 16 µg/ml. The two samples were detected by Phalanx Human OneArray(®) Annotation HOA v7 release 1.0 with 31,741 mRNA probes and 20,672 genes in the human genome
|
| |
|
| Contributor(s) |
YE J, ZHANG Z |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jul 12, 2017 |
| Last update date |
Jul 25, 2021 |
| Contact name |
jingjing wang |
| Organization name |
NA
|
| Street address |
WENYI WEST road
|
| City |
hangzhou |
| ZIP/Postal code |
310000 |
| Country |
China |
| |
|
| Platforms (1) |
| GPL21282 |
Phalanx Human OneArray Ver. 7 Release 1 |
|
| Samples (2) |
|
| Relations |
| BioProject |
PRJNA393976 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE101305_RAW.tar |
3.2 Mb |
(http)(custom) |
TAR (of GPR) |
| GSE101305_raw_signals_with_det-p-val.txt.gz |
497.3 Kb |
(ftp)(http) |
TXT |
| Processed data included within Sample table |
|
|
|
|
 |
